After witnessing 10 years of breakthroughs across the spectrum of cancer care, oncology experts are looking ahead as a new decade begins to capitalize on those wide-ranging therapeutic and diagnostic gains. To find out what might be on the horizon for 2020, OncologyLive®
reached out to prominent leaders in the field. Their overall take: Developments in unraveling resistance to immune checkpoint inhibitor (ICI) therapy and molecular diagnostics will be the most active areas of research in 2020.
The experts made their observations against a backdrop of remarkable, practice-changing advancements. Since 2010, major oncology trends include the broad adoption of ICIs, the development of new classes of agents targeting molecular drivers of malignancies, and the introduction of genetically modified T-cell therapies.
In 2019 alone, the FDA approved the first PD-1/PD-L1–target-ing immunotherapy, atezolizumab (Tecentriq), for patients with triple-negative breast cancer (TNBC); the first targeted therapy, erdafitinib (Balversa), for urothelial carcinoma; and 2 new therapies for hepatocellular carcinoma, ramucirumab (Cyramza) and cabozantinib (Cabometyx).1Lung Cancer
Edward S. Kim, MD
... to read the full story